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Summary We carried out an immunohistochemical study and DNA analysis of 30 gastric carcinomas to
evaluate p53 overexpression and allelic loss at 17p. The immunohistochemical study demonstrated
immunoreactivity for p53 protein in four cases. Allelic loss for the pYNZ22.1 marker was detected in nine
cases. In total, ten cases showed immunoreactivity for p53 protein, allelic loss, or both. The study of nine of
these cases by constant denaturant gel electrophoresis revealed p53 mutations in three cases. We conclude that
the prevalence ofmutations of p53 in our series is similar to what has recently been observed in other cases of
gastric cancer, but lower than in colon carcinomas.
The p53 gene is localised to chromosome arm 17pl3 (McBride
et al., 1986) and codes for a 53,000 dalton nuclear protein
regulating the cell cycle in a yet unclarified way (Levine,
1990; Mercer et al., 1984). Evidence from in vitro models
suggests that p53 acts as a tumour suppressor gene (Finlay et
al., 1989). Deletions of chromosome 17 alleles associated with
a mutant p53 in human cancer (Baker et al., 1989) lent
further support to the tumour suppressor gene hypothesis
(Knudson, 1985). Mutations of p53 and/or allelic loss at 17p
have been reported in an increasing number of different
human malignancies: colon (Baker et al., 1989; Baker et al.,
1990), breast (Nigro et al., 1989; Thompson et al., 1990;
B0rresen et al., 1991), lung (Nigro et al., 1989; Iggo et al.,
1990), brain (Nigro et al., 1989), bone (Masuda et al., 1987),
and esophagus (Hollstein et al., 1990). The evidence
accumulated so far suggests that mutant p53 may be the
commonest genetic abnormality in human cancer (Harris,
1990). Nigro et al. (1989) showed that p53 mutations cluster
in four hot-spots localised in the most conserved region of
the gene. Immunohistochemical studies show that antibodies
raised against mutant p53 proteins and the wild-type counter-
part (complexed and inactivated by the trans-dominant
mutant p53 protein product) may be used as screening
method for the presence of mutations (Iggo et al., 1990).
Accordingly, detectable levels of p53 protein product by
immunohistochemistry suggest the existence of genetic altera-
tions at this locus, since the very low steady-state levels of
the normal protein (due to its rapid turn-over) are usually
invisible by this method (Rodrigues et al., 1990).
Masuda et al. (1987) studied the importance of p53
deletion/mutation/protein overexpression in gastric cancer in
five cases, and found no abnormalities. Very recently, while
our work was in progress, Tamura et al. (1991) reported on
p53 mutations in nine out of 24 specimens of primary gastric
cancers, all of them being aneuploid.
We undertook DNA analysis and immunohistochemical
study of 30 gastric carcinomas consecutively diagnosed in our
Department to evaluate p53 protein overexpression, allelic
loss, and mutations. Frozen specimens of gastric tumours
and respective non-neoplastic mucosa were available for
DNA analysis. Formalin-fixed and paraffin-embedded material
from the same cases were available for immunohistochemial
study.
High-molecular-weight DNA was isolated using standard
procedures (Miillenbach et al., 1989). For loss of
heterozygosity (LOH) studies DNA was digested with the
restriction enzymes Taq I and Rsa I, and Southern blot
membranes were hybridised with probe pYNZ22.1 (17pl3.3).
Cases showing LOH with probe pYNZ22.1 were further
studied for the p53 locus with probe pBHP53. These samples
were also screened for p53 mutations using constant
denaturant gel electrophoresis (CDGE), after PCR amplifi-
cation using four sets of primers, each specific for one of the
four hot-spots where most p53 mutations have previously
been identified. The melting behaviour of the suspect mutants
was compared with the melting behaviour of normal DNA in
perpendicular denaturant gradient gels, to confirm that an
aberrant migrating band on CDGE was a true mutant
(B0rresen et al., 1991). Sequencing of the samples with the
mutations detected by CDGE was also performed using PCR
for direct sequencing. PCR was performed with one
biotinylated primer. The biotinylated PCR products were
sequenced directly with standard dideoxy sequencing reac-
tions using Dynabeads M280-Streptavidin (Dynal AS, Nor-
way) as solid support (Hultman et al., 1989). Sections from
paraffin-embedded material were immunostained using a
monoclonal antibody detecting both wild-type and mutant
p53 (PAb 1801 - Oncogene Science). Incubation with the
primary antibody was performed in dilution 1:100
(1 pig IgG, ml-') overnight. The avidin-biotin-peroxidase
complex method was used (Hsu et al., 1981). Positive and
negative (incubation with mouse myelom protein - IgG,
gLg ml- 1) controls were included.
Nine out of 24 informative cases (37.5%) showed LOH
with pYNZ22.1. Seven of these cases were further studied
with probe BHP53 and LOH for this locus was detected in
the only informative case. Four out of the 30 cases (13.3%)
showed nuclear immunoreactivity of the neoplastic cells. Ten
cases had LOH, positive immunostaining or both (Table I).
Previous reports establishing the value of screening for muta-
tions using both immunohistochemistry (Iggo et al., 1990)
and LOH studies with pYNZ22.1 (Baker et al., 1990), promp-
ted us to search for mutations of p53 in the ten cases selected
by these methods (immunoreactive, LOH of 17p or both).
One case with LOH, non-immunoreactive, could not be fur-
ther evaluated because no more DNA was available. Nine
cases were further screened for mutations. Three of these
nine cases showed PCR products with a mobility different
from normal DNA in the CDGE (Figure 1), strongly sugges-
ting the presence of mutations
- two cases in hot-spot B
(exon 5, codon 155-185) and one in hot-spot D (exon 8,
codon 265-301). Perpendicular denaturing gradient gels were
performed to visualise the PCR products profile. In every
case a distinct denaturing profile was observed, different from
the normal one, reinforcing the CDGE results. Sequencing
was performed and confirmed the presence of mutations in
all three cases (Table I). Immunoreactivity was observed more
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Table I Immunostaining and LOH results; hot-spots involved and mutation sequence
LOH
Immunoreactivity pyNZ22.1 pBHP53 Hot-spots involved Mutation sequence
Case 1 - + + B (codon 175) CGC-*CAC (arg hist)
Case 2 - + NI b
Case 3 + _ a B (codon 173) GTG-*ATG (val-met)
Case 4 - + NI b
Case5 - + NI b
Case 6 + + a D (codon 273) CGT-*TGT (arg*cys)
Case 7 - + NI b
Case 8 + + NI b
Case 9 + + NI b
Case 1 - + a a b
'DNA was not available for analysis. bAnalysis not performed. NI - not informative.
-~~ 0
Figure 1 Constant denaturant gels of tumour DNA from the
three cases with p53 mutations and normal controls. a, PCR
amplified fragment B run at 54% denaturant from a normal
control (left) and from case 1 (right). b, PCR amplified fragment
B run at 54% denaturant from case 3. c, PCR amplified fragmnent
D run at 46% denaturant from a normal control (left) and from
case 6 (right).
frequently (P = 0.099) in cases with LOH (three of nine cases
- 33.3%) than in cases without LOH (one of 15 cases - 6.7%).
The number of analysed cases is too small to allow definite
conclusions on the relationship between immunoreactivity and
mutations although two out of three mutations (66.7%) occur-
red in immunoreactive tumours. The same applies to the
relationship between the presence of mutations and LOH with
pYNZ22.1: two out of the three mutations (66.7%) occurred
in tumours with LOH but seven cases had LOH and no
detectable mutations in the screened regions (Table I). This
discrepancy between LOH for pYNZ22.1 and p53 mutations is
most likely due to the different location of the region detected
by pYNZ22.1 and the p53 gene itself (Human Gene Mapping
10, 1989), although mutations outside the screened regions
could not be excluded. The low informativity of pBHP53 did
not allow the estimation of the relationship between the
presence of mutations and LOH with this probe in our series.
Our study shows that the prevalence of mutations of p53
in gastric carcinomas as assessed by immunohistochemical
detection (13.3%) and by mutation (three out of nine cases
studied by CDGE, i.e., 33.3%) is in the same order of
magnitude as in the breast (B0rresen et al., 1991), and in the
recent report by Tamura et al. (1991) in gastric carcinomas,
but lower than those reported for colon carcinomas (Scott et
al., 1991). It also shows that in gastric carcinomas, as
elsewhere (Nigro et al., 1989) there seems to be a clustering
of mutations (at least) in some of the p53 hot-spots. How-
ever, the presence of immunoreactivity in two cases that did
not show p53 mutations may be due to mutations occurring
outside the four hot-spots studied or elevated level of the
normal p53 protein. Alternatively, a sampling bias due to
contamination by non-neoplastic (stromal) cells and subse-
quent preferential PCR amplification of normal sequences
might explain the observed 'false-negative' results.
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